Discontinued — last reported Q3 '25
Royalty Pharma Less: net unamortized discount decreased by 2.4% to $223.56M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.5%, from $182.55M to $223.56M. Over 5 years (FY 2020 to FY 2025), Less: net unamortized discount shows an upward trend with a 4.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A large unamortized discount indicates significant debt issued at a price below par, often due to interest rate environments at the time of issuance.
This represents the difference between the face value of debt and the proceeds received at issuance, which is being amor...
Standard accounting adjustment for debt instruments across all capital-intensive companies.
other_debt_instrument_unamortized_discount| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $174.44M | $209.33M | $203.93M | $198.86M | $193.80M | $188.74M | $183.68M | $178.62M | $173.56M | $168.81M | $164.72M | $160.62M | $197.98M | $192.62M | $187.57M | $182.55M | $177.50M | $234.27M | $229.08M | $223.56M |
| QoQ Change | — | +20.0% | -2.6% | -2.5% | -2.5% | -2.6% | -2.7% | -2.8% | -2.8% | -2.7% | -2.4% | -2.5% | +23.3% | -2.7% | -2.6% | -2.7% | -2.8% | +32.0% | -2.2% | -2.4% |
| YoY Change | — | — | — | — | +11.1% | -9.8% | -9.9% | -10.2% | -10.4% | -10.6% | -10.3% | -10.1% | +14.1% | +14.1% | +13.9% | +13.6% | -10.3% | +21.6% | +22.1% | +22.5% |